

Almirall at a glance

Who we are

We are a global pharmaceutical company dedicated to medical dermatology. As a family-owned business, we think in generations and apply this long-term view to our contributions to people with skin conditions, placing patients at the center of our business ambitions.



Headquartered in
Barcelona

Offices around the world
14

Total employees
2,026

Country presence
+100

Patients at the core

Number of products

145

Dermatology products

55

Patients we have helped with our key dermatology products¹

684,500

¹ The total number includes Klisyri® (tirbanibulin), Ilumetri® (tildrakizumab), Wynzora® (calcipotriol/betamethasone) and Ebglyss® (lebrikizumab) in 2024.

Our therapeutic focus

Immune inflammatory diseases

Atopic dermatitis
Psoriasis
Hidradenitis suppurativa
Alopecia areata
Vitiligo

Non-melanoma skin cancer

Actinic keratosis
Basal cell carcinoma
Cutaneous T-cell lymphoma
Squamous cell carcinoma

Rare diseases

Autoimmune bullous diseases
Epidermolysis bullosa
Palmoplantar pustulosis

What we do

With an R&D pipeline solely focused on medical dermatology, we are at the forefront of science to develop and deliver ground-breaking, differentiated end-to-end products that address patients' needs. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose of improving patients' lives holistically.



Driven by innovation

Investment of Net Sales in R&D	Current projects in the pipeline	Current collaborations and partnerships in R&D
12.6%	13	22

Collaborative mindset

Assets	Academic	Tech Platforms
Ichnos	Hospital Sant Pau	Evotec (Multi-target alliance for NCEs integrated discovery platform)
Simcere	Biomap IMI	Ablexis / AlivaMab (Multi-target alliance for antibody drug discovery)
Eli Lilly	University of Dundee	Epimab (License to develop up to three bispecific antibody targets)
Isolex (development of novel approaches for IgE-mediated diseases)	IRB Barcelona	Absci (Multi-target alliance for AI based antibody discovery)
Kaken	University of Michigan	Etherna (Multi-target alliance to develop mRNA-based therapies)
MC2	ARTIBAND	* Microsoft
Paratek	CRG	
*Novo Nordisk (NN-8828 for immune inflammatory dermatological diseases)		
*Eloxx (ZKN-013 for rare dermatological diseases)		

*Signed in 2024

Almirall innovation Hub **The Hive**. A collaborative and unique innovation ecosystem aimed at advancing scientific breakthroughs and enhancing research success.



Pipeline

Molecule name	Indication	Phase I	Phase II	Phase III	Registration	Geography
Sarecycline	Acne	Progressing				China
Tirbanibulin	Actinic keratosis (LF)	Completed	Progressing			Europa
Tildrakizumab	Psoriatic arthritis	Completed	Progressing			Europa
Lebrikizumab	Atopic Dermatitis pediatric	Completed	Progressing			Europa
Anti-IL-21 mAb	Inflammatory skin disease	Progressing				Worldwide
Anti-IL-1RAP mAb	Hidradenitis Suppurativa	Progressing				Worldwide
IL-2muFc*	Inflammatory skin disease	Progressing				Worldwide
ZKN-013**	Rare dermatology (RDEB/JEB)	Progressing				Worldwide

*Worldwide ex- Greater China

**EBDR/EBJ: Epidermólisis Bullosa Distrófica Recesiva / Epidermólisis Bullosa Juncional

Our 2030 Sustainability Strategy

Act for impact is a strategic factor in our plan to make a meaningful and lasting difference in society and the environment while upholding its core principles of transparency, responsibility, ethics, and compliance.

GOING BEYOND FOR A GREATER IMPACT

Planet

Take bold action on climate through our science-led **Net Zero Emissions Strategy**, delivering our energy decarbonisation, sustainable mobility and sustainable procurement plans. Promote actions towards **water stewardship, circular economy, and nature protection**.



People

Implement a **Global Diversity, Equity and Inclusion Plan**, enhance our **Talent Management** to unleash our employees full potential, deploy our corporate holistic **Wellbeing Programme** and consolidate a Corporate **Volunteering Programme**.



Patients

Strengthen our commitment to patients through our **Patient Organisations Engagement Plan** with a special focus on our derma patient's wellbeing. Reinforce a **Patient Centric Mindset** across all Almirall and prioritize the needs of patients, putting them at the core of our decisions.



Partners

Deploy our **sustainable procurement programme**, through an enhanced **Supplier Risk Management Process**, implementing tools and platforms to support the process, ensuring effective governance and reinforcing **sustainability-related aspects** in the relationship with our value chain.



Principles

Further integrate sustainability into the company's strategy and governance, increase our transparency by continuing **to report to best-in-class ESG** rating agencies and ensure an **ethical culture and mindset**, being **accountable** in all our actions.



Sustainability & ESG Ratings:

